Superworth

Regeneron Pharmaceuticals REGN

Biotechnology, Healthcare
$970.82
+0.99%
Market cap
$100B
PE
24.0×
10y median 19.7×
Forward PE
15.1×
10y median 17.3×
Price to sales
6.4×
EV/EBIT
18.8×
Revenue, 12 months
$15.5B
+9% on a year ago
Net margin
27.9%
Free cash flow yield
3.8%

Regeneron Pharmaceuticals trades at 24.0× trailing earnings, pricier than 65% of the last ten years. Revenue was $15.5B over the last twelve months, up 9% on a year earlier with a 28% net margin.

Charts

Financials

Income statement for REGN, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$3.4B+15%$3.4B+1%$3.1B−1%$3.5B+12%$3.7B+11%$3.8B+10%$3B−4%$3.7B+4%$3.8B+1%$3.9B+3%$3.6B+19%$4.3B+17%
Cost of revenue$436.4M+37%$517M−4%$433.8M−5%$480.2M+19%$491.1M+13%$565.4M+9%$464.3M+7%$530.2M+10%$521.6M+6%$584.6M+3%$669.4M+44%$576.5M+9%
Gross profit$2.9B+12%$2.9B+2%$2.7B+0%$3.1B+11%$3.2B+10%$3.2B+11%$2.6B−5%$3.1B+3%$3.2B+0%$3.3B+2%$2.9B+15%$3.7B+18%
R&D$1.1B+18%$1.2B+13%$1.2B+13%$1.2B+11%$1.3B+18%$1.4B+20%$1.3B+6%$1.4B+19%$1.5B+16%$1.6B+15%$1.5B+16%$1.6B+15%
SG&A$640.5M+21%$737.7M+12%$689M+15%$758.8M+16%$714.4M+12%$792.2M+7%$633M−8%$634.2M−16%$657.8M−8%$775M−2%$647.7M+2%$662.1M+4%
$1.1B−9%$972.9M−15%$751.4M−21%$1.1B+5%$1.2B+6%$990.2M+2%$591.7M−21%$1.1B+1%$1B−13%$879.9M−11%$642.9M+9%$1.3B+20%
Interest expense$17.8M+16%$18.3M+5%$16.1M−11%$14.8M−22%$13.8M−23%$10.5M−43%$8.7M−46%$3.6M−76%$19.3M+40%$12.2M+16%$12.9M+48%$11M+206%
Pre-tax income$1.1B−26%$1.1B−13%$700.7M−18%$1.6B+50%$1.5B+34%$958.1M−17%$905M+29%$1.5B−7%$1.8B+18%$1B+9%$831.2M−8%$1.5B+1%
$103M−47%−$12M−$21.3M$195.8M+71%$152.4M+48%$40.4M$96.3M$127.1M−35%$303.3M+99%$199.1M+393%$104M+8%$230.9M+82%
Net income$1B−23%$1.2B−3%$722M−12%$1.4B+48%$1.3B+33%$917.7M−21%$808.7M+12%$1.4B−3%$1.5B+9%$844.6M−8%$727.2M−10%$1.3B−7%
$8.89−24%$10.20−3%$6.27−13%$12.41+46%$11.54+30%$8.08−21%$7.27+16%$12.81+3%$13.62+18%$7.84−3%$6.75−7%$12.23−5%
113.4M+1%113.7M−0%115.1M+1%115.4M+1%116.2M+3%113.6M−0%111.2M−3%108.6M−6%107.2M−8%107.7M−5%107.7M−3%106M−2%

Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 13 periods, Q2 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY09 to Q4 FY11: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 14 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$4.6B$4.4B to $4.7B$16.51$15.60 to $17.6215
Q4 FY26$5.8B$5B to $6.5B$24.48$18.60 to $31.7814
Q1 FY27$4.6B$4.5B to $4.7B$15.95$13.94 to $17.396
Q2 FY27$5.1B$4.5B to $5.6B$19.08$16.22 to $21.082
Q3 FY27$5.3B$4.7B to $5.7B$19.39$16.49 to $21.432
Q4 FY27$5.6B$4.9B to $6B$20.81$17.69 to $23.002
Q1 FY28$4.9B$4.3B to $5.3B$17.86$15.19 to $19.745
Q2 FY28$5.4B$4.8B to $5.9B$20.84$17.71 to $23.025

Peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
REGNRegeneron Pharmaceuticals$100B24.0×19.7×15.1×6.4×+9%27.9%
VRTXVertex Pharmaceuticals$137.1B31.5×28.6×27.9×10.9×+10%35.0%
ONCBeOne Medicines$40.2B63.2×67.6×45.0×6.6×+34%10.7%
UTHRUnited Therapeutics$25.9B21.6×14.2×22.6×8.2×+2%41.6%
INCYIncyte$24.3B15.3×36.5×51.3×4.2×+27%27.7%
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×n/m4.4×+34%20.9%
HALOHalozyme Therapeutics$14.6B38.5×21.3×n/m8.8×+41%24.9%
TECHBIO-TECHNE$11.4B63.2×62.0×n/m9.4×−0%15.0%
Peer median$21.2B26.7×36.5×27.9×7.1×+27%24.9%

More on Regeneron Pharmaceuticals

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .